Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2.

P. Kosmidis; Konstantinos Syrigos; Haralabos P. Kalofonos; Meletios A Dimopoulos; Dimosthenis Skarlos; N Pavlidis; Ioannis Boukovinas; Dimitrios Bafaloukos; Dimitrios Pectasides; C. Bacoyiannis; George Fountzilas

Abstract

1 min read

No significant difference was found in clinical benefit between PS:2 NSCLC patients treated with either vinorelbine or paclitaxel.

Related publications

Article2009

Paclitaxel/gemcitabine versus paclitaxel/vinorelbine in advanced non-small cell lung cancer (NSCLC): A phase III randomized study

P. Kosmidis, Eleni Timotheadou, Αngelos Koutras, George Pentheroudakis, C. Christodoulou, Meletios A Dimopoulos, D. Bafaloukos, E. Samantas, Dimitrios Pectasides, K. Syrigos

Article2005

Paclitaxel and gemcitabine vs carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable non-small cell lung cancer (NSCLC)

P. Kosmidis, Haralabos P. Kalofonos, K. Syrigos, D. Skarlos, George Fountzilas, C. Nicolaides, D. Bafaloukos, E. Samantas, C. Bakogiannis, Meletios A Dimopoulos

Article1997

Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen.

Vassilis Georgoulias, C. Kourousis, Stylianos Kakolyris, N. Androulakis, Meletios A Dimopoulos, E. Papadakis, Thanos Kotsakis, N. Vardakis, K. Kalbakis, N. Merambeliotakis, Dora Hatzidaki

Article2018

Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)

Anna Tsiara, Michalis Liontos, Μαρία Καπαρέλου, Roubini Zakopoulou, Aristotelis Bamias, Meletios A Dimopoulos

Article2004

A retrospective study of gefitinib effective cases in non-small cell lung cancer patients with poor performance status

Hikaru Nakamura, Masahiko Azuma, Shun Namisato, Teruhito Uchihara, A. Saito, Makoto Furugen, Shuzo Teruya, H. Higa